Healthcare Cost and Utilization Associated with Biologic Treatment Patterns Among Patients with Psoriatic Arthritis: Ana
- PDF / 761,162 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 28 Downloads / 200 Views
ORIGINAL RESEARCH ARTICLE
Healthcare Cost and Utilization Associated with Biologic Treatment Patterns Among Patients with Psoriatic Arthritis: Analyses from a Large US Claims Database Peter Hur1 · Nina Kim2,3 · Dong Dai1 · Olivia W. Piao4 · Josh Z. Zheng4 · Esther Yi1 Accepted: 24 October 2020 © The Author(s) 2020
Abstract Background Costs associated with biologic switching and discontinuation can be high in psoriatic arthritis (PsA), and their inappropriate use may have cost implications for patients, healthcare professionals, and payers. Objective To compare direct costs of treatment switchers, non-switchers, and discontinuers among patients with PsA who newly initiated a biologic. Methods Patients with PsA aged ≥ 18 years with ≥ 1 pharmacy claim for an FDA-approved subcutaneous biologic from 1 January 2016 to 31 December 2016 were identified from the Truven Health MarketScan Databases. Patients were categorized into three mutually exclusive groups of non-switchers, switchers, and discontinuers, and healthcare costs and utilization during 1-year follow-up were described across the three groups separately. Results A total of 2560 patients with PsA newly initiating a biologic were categorized as non-switchers (54.8%), switchers (18.5%), and discontinuers (26.7%). During 1-year follow-up, after adjusting for age, sex, full-time work status, and co-morbidities, switchers had higher mean total all-cause healthcare costs than non-switchers (US$80,380 vs. US$69,031), driven by increased pharmacy (US$66,531 vs. US$56,674) and outpatient (US$10,881 vs. US$8,235) costs (all P < 0.0001). Discontinuers had the lowest mean total all-cause healthcare costs (US$50,054) but the highest medical costs (US$20,323). Switchers and discontinuers had higher all-cause healthcare utilization than non-switchers during 1-year follow-up, except switchers had fewer hospitalizations. Conclusions Patients with PsA who switch or discontinue biologics have higher medical costs and healthcare utilization than those continuing the same biologic. These findings highlight that discontinuing or switching biologic therapies is associated with higher costs in patients with PsA, which may inform treatment and/or formulary decision-making.
Key Points Within 1 year of initiating a subcutaneous biologic, 54.8% of patients with PsA remained on their index biologic, 18.5% switched from their index biologic to a new therapy, and 26.7% discontinued their index biologic.
* Peter Hur [email protected] 1
Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936‑1080, USA
2
University of Texas at Austin, Austin, TX, USA
3
Baylor Scott & White Health, Temple, TX, USA
4
KMK Consulting, Inc, East Hanover, NJ, USA
Compared with non-switchers, switchers had higher total all-cause healthcare costs, which were driven by increased prescription and medical costs; discontinuers had lower all-cause healthcare costs but the highest medical costs, potentially due to active disease. Switchers and discontinuers had increase
Data Loading...
